CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling

Samantha M. Fix(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Ana Lucía Dominguez(The University of Texas MD Anderson Cancer Center), Rafet Başar(The University of Texas MD Anderson Cancer Center), Patrick Hwu(Moffitt Cancer Center), Donastas Sakellariou-Thompson(The University of Texas MD Anderson Cancer Center), Sanjay Kumar(Uttarakhand State Council for Science and Technology), Cara Haymaker(The University of Texas MD Anderson Cancer Center), Chantale Bernatchez(BMC Software (United States)), Minjung Lee(The University of Texas MD Anderson Cancer Center), Tamara Griffiths(The University of Texas MD Anderson Cancer Center), Yunfei Wang(The University of Texas MD Anderson Cancer Center), Larissa A. Meyer, Christopher Reyes(Thermo Fisher Scientific (United States)), Marie‐Andrée Forget(The University of Texas MD Anderson Cancer Center)
Journal for ImmunoTherapy of Cancer
July 1, 2022
Cited by 44


Related Papers